Open Interest Spike and Volume Analysis
On 31 Jul 2026, Mankind Pharma’s open interest (OI) in derivatives surged by 7,100 contracts, a 39.17% increase from the previous day’s 18,126 to 25,226 contracts. This sharp rise in OI accompanied a total volume of 36,227 contracts traded, indicating robust participation from traders and investors. The futures segment alone accounted for a notional value of approximately ₹34,298 lakhs, while options contracts represented a staggering ₹19,730.96 crores in value, underscoring the scale of derivatives activity.
The underlying stock price closed at ₹2,430, having experienced a day’s low of ₹2,422, down 5.97% intraday. The weighted average price skewed closer to the low end, suggesting selling pressure dominated the session. Notably, the stock underperformed its sector by 6.13% and the broader Sensex by 5.05% on the day, reflecting a cautious or bearish sentiment among market participants.
Market Positioning and Directional Bets
The surge in open interest amid falling prices typically signals fresh short positions or increased hedging activity. Given Mankind Pharma’s three-day consecutive decline, with a cumulative loss of 6.87%, the rising OI suggests that traders may be positioning for further downside or volatility. The high intraday volatility of 6.39% corroborates this view, as market participants adjust their exposures in response to evolving fundamentals or technical triggers.
Interestingly, the stock’s price remains above its 100-day and 200-day moving averages but below the shorter-term 5-day, 20-day, and 50-day averages. This technical setup often indicates a medium-term bullish trend under pressure from short-term selling, which can attract speculative activity in derivatives markets. The delivery volume of 1.67 lakh shares on 30 Jul 2026, slightly down by 0.47% against the five-day average, points to a marginal decline in long-term investor participation, possibly due to profit booking or risk aversion.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Implications for Investors and Traders
The marked increase in open interest combined with elevated volumes and volatility suggests that Mankind Pharma is at a critical juncture. The stock’s Mojo Score of 72.0 and an upgraded Mojo Grade from Hold to Buy as of 29 Jul 2026 indicate improving fundamentals and positive medium-term prospects. However, the recent price weakness and derivatives activity imply that market participants are hedging against near-term risks or speculating on further price corrections.
Investors should note that the stock’s market capitalisation stands at ₹1,01,204.66 crores, categorising it as a mid-cap entity within the Pharmaceuticals & Biotechnology sector. This positioning often attracts both institutional and retail interest, especially when sectoral trends are mixed. The sector’s 1-day return of 1.08% contrasts with Mankind Pharma’s 4.87% decline, highlighting stock-specific pressures possibly linked to earnings expectations, regulatory developments, or competitive dynamics.
Technical and Fundamental Outlook
From a technical perspective, the stock’s position above long-term moving averages provides a support cushion, but the breach of shorter-term averages signals caution. The high intraday volatility and volume concentration near the lows suggest that bears currently hold the upper hand, but the sizeable open interest build-up could also indicate that some traders are preparing for a reversal or a volatility spike.
Fundamentally, Mankind Pharma’s upgrade to a Buy rating by MarketsMOJO reflects confidence in its earnings growth, product pipeline, and market share expansion. The company’s presence in the Pharmaceuticals & Biotechnology sector, which remains a defensive and growth-oriented segment, adds to its appeal amid broader market uncertainties.
Want to dive deeper on Mankind Pharma Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Conclusion: Navigating Volatility and Positioning
The recent surge in open interest for Mankind Pharma Ltd’s derivatives signals a pivotal moment for the stock. While the underlying price has declined over the past three sessions, the increased activity in futures and options contracts points to a market bracing for further movement, whether continuation of the downtrend or a potential rebound.
Investors and traders should carefully monitor volume patterns, price action relative to moving averages, and sectoral trends to gauge the stock’s trajectory. The upgraded Mojo Grade to Buy and a solid Mojo Score of 72.0 provide a fundamental backdrop supporting medium-term optimism, but the current derivatives positioning and volatility caution against complacency.
Given the stock’s liquidity, with a tradable size of approximately ₹1.8 crores based on recent volumes, market participants can efficiently enter or exit positions. However, the mixed signals warrant a balanced approach, combining technical analysis with fundamental insights to capitalise on opportunities while managing risk effectively.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
